Skip to main content
Journal cover image

Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).

Publication ,  Journal Article
Rebeiz, AG; Dery, J-P; Tsiatis, AA; O'shea, JC; Johnson, BA; Hellkamp, AS; Pieper, KS; Gilchrist, IC; Slater, J; Muhlestein, JB; Joseph, D ...
Published in: Am J Cardiol
October 1, 2004

Although randomized trials have clearly demonstrated the clinical efficacy with regimens of platelet glycoprotein IIb/IIIa antagonists that result in >80% inhibition of baseline platelet aggregation in percutaneous coronary intervention (PCI), there are no data available concerning the optimal duration of infusion of these agents. In an era when the length of hospitalization has a major impact on health care costs, the determination of the optimal duration of the infusion of these drugs after PCI is of great relevance. The investigators therefore sought to determine the optimal length of the infusion of eptifibatide after PCI by analyzing the outcomes of patients enrolled in the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy trial who were randomized to treatment with eptifibatide.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

October 1, 2004

Volume

94

Issue

7

Start / End Page

926 / 929

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Postoperative Complications
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides
  • North America
  • Myocardial Infarction
  • Isoenzymes
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rebeiz, A. G., Dery, J.-P., Tsiatis, A. A., O’shea, J. C., Johnson, B. A., Hellkamp, A. S., … ESPRIT substudy, . (2004). Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). Am J Cardiol, 94(7), 926–929. https://doi.org/10.1016/j.amjcard.2004.06.030
Rebeiz, Abdallah G., Jean-Pierre Dery, Anastasios A. Tsiatis, J Conor O’shea, Brent A. Johnson, Anne S. Hellkamp, Karen S. Pieper, et al. “Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).Am J Cardiol 94, no. 7 (October 1, 2004): 926–29. https://doi.org/10.1016/j.amjcard.2004.06.030.
Rebeiz AG, Dery J-P, Tsiatis AA, O’shea JC, Johnson BA, Hellkamp AS, et al. Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). Am J Cardiol. 2004 Oct 1;94(7):926–9.
Rebeiz, Abdallah G., et al. “Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy).Am J Cardiol, vol. 94, no. 7, Oct. 2004, pp. 926–29. Pubmed, doi:10.1016/j.amjcard.2004.06.030.
Rebeiz AG, Dery J-P, Tsiatis AA, O’shea JC, Johnson BA, Hellkamp AS, Pieper KS, Gilchrist IC, Slater J, Muhlestein JB, Joseph D, Kitt MM, Tcheng JE, ESPRIT substudy. Optimal duration of eptifibatide infusion in percutaneous coronary intervention (an ESPRIT substudy). Am J Cardiol. 2004 Oct 1;94(7):926–929.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

October 1, 2004

Volume

94

Issue

7

Start / End Page

926 / 929

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Survival Analysis
  • Postoperative Complications
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Platelet Aggregation Inhibitors
  • Peptides
  • North America
  • Myocardial Infarction
  • Isoenzymes